Penumbra Inc (NYSE:PEN) Director Bridget O’rourke sold 1,200 shares of the firm’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $142.19, for a total value of $170,628.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Penumbra stock traded down $3.02 during midday trading on Thursday, reaching $136.31. 566,100 shares of the company were exchanged, compared to its average volume of 332,614. The stock has a market cap of $4.81 billion, a PE ratio of -13,600.00, a P/E/G ratio of 14.67 and a beta of 0.40. Penumbra Inc has a 1 year low of $82.55 and a 1 year high of $167.35.
Penumbra (NYSE:PEN) last posted its quarterly earnings data on Monday, November 5th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.14. The firm had revenue of $111.80 million during the quarter, compared to analysts’ expectations of $103.59 million. Penumbra had a return on equity of 4.21% and a net margin of 2.15%. The firm’s quarterly revenue was up 33.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.01 EPS. Equities research analysts predict that Penumbra Inc will post 0.47 EPS for the current fiscal year.
A number of brokerages have recently weighed in on PEN. TheStreet upgraded Penumbra from a “d+” rating to a “c” rating in a research report on Monday, September 17th. ValuEngine upgraded Penumbra from a “hold” rating to a “buy” rating in a research report on Wednesday, September 12th. Zacks Investment Research upgraded Penumbra from a “hold” rating to a “buy” rating and set a $157.00 price target for the company in a research report on Wednesday, November 7th. BMO Capital Markets raised their price target on Penumbra from $150.00 to $152.00 and gave the company a “market perform” rating in a research report on Tuesday, November 6th. Finally, Bank of America restated a “buy” rating and issued a $36.00 price target on shares of Penumbra in a research report on Monday, October 29th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $145.57.
Institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP purchased a new stake in Penumbra during the 2nd quarter worth about $1,530,000. Cubist Systematic Strategies LLC increased its position in Penumbra by 792.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 52,520 shares of the company’s stock worth $7,256,000 after purchasing an additional 46,637 shares in the last quarter. Great West Life Assurance Co. Can increased its position in Penumbra by 17.8% during the 2nd quarter. Great West Life Assurance Co. Can now owns 3,230 shares of the company’s stock worth $446,000 after purchasing an additional 489 shares in the last quarter. First Trust Advisors LP increased its position in Penumbra by 23.8% during the 2nd quarter. First Trust Advisors LP now owns 66,419 shares of the company’s stock worth $9,176,000 after purchasing an additional 12,755 shares in the last quarter. Finally, OppenheimerFunds Inc. increased its position in Penumbra by 3.1% during the 2nd quarter. OppenheimerFunds Inc. now owns 245,675 shares of the company’s stock worth $33,939,000 after purchasing an additional 7,444 shares in the last quarter. Hedge funds and other institutional investors own 72.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/12/06/penumbra-inc-pen-director-sells-170628-00-in-stock.html.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
See Also: Reverse Stock Split
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.